On Monday 27 February the ABPI is hosting a parliamentary event discussion on innovation and commercial success that will be hosted by Andrew Miller MP.


The event, due to be held at the Attlee Suite of Portcullis House at the Houses of Parliament, is being held to highlight the launch of the Science in Parliament Spring Issue, which features a number of articles examining current issues and developments in the bio-pharma sector. Science in Parliament is the Journal of the Parliamentary and Scientific Committee.

Join Andrew Miller MP as he discusses why innovation and commercial success are so important to the UK, ABPI CEO Stephen Whitehead who will focus on innovation in pharma, Lord Drayson who will examine the role of innovation in other industries, and Bettina Fitt of GE Healthcare who will provide the perspective of a global innovative company.

Stephen Whitehead, CEO of the ABPI, said:

“The parliamentary event discussion and the launch of the Science in Parliament Spring Issue both serve to highlight how important innovation is: Innovation is fundamental for the on-going success of our industry, it is critical to the future wellbeing of our healthcare economy, and it is the key to fulfilling future unmet clinical need.”

The Science in Parliament Spring Issue will include the following articles, which are available for review on request:

  • David Willetts MP: Investing in UK Health and Life Sciences
  • Nick Burgin: The Innovation Review – an Industry Response
  • Sir Mark Walport FRS: Unlocking Patient Data for Better Care and Research
  • Samantha Marshall: Putting Data at the Heart of our Healthcare Industry
  • Dr Adrian Towse: Cost-per-QALY in the US and Britain: Damned if you do and Damned if you don’t
  • John Irwin: Standing up for Orphans
  • Dr Allison Jeynes-Ellis: What is Medical innovation?
  • Dr Maggy Jennings OBE: Implications of the new EU Directive Regulating Animal Experiments for the UK
  • Barbara Davies: What do you need to Know about Animal Research Today?
  • Andy Powrie-Smith: Transparency in Clinical Research
  • Dr Paul Whittaker and Professor Chris Brightling: Putting COPD on the map – Collaborating to Fight Disease
  • Paul Duckett: Astra Zeneca Brixham
  • Glyn Edwards: Valley of Death
  • Dr Louise Leong: Stratified Medicines: The Future of Healthcare
  • Professor Frank Bonner: Stem cells for Safer medicines: A Predictive Toxicology Consortium
  • Eric Low: Stakeholder Perspectives on Value-Based Pricing
  • Dr Mark Down, FSB, FLS: Society of Biology Degree Accreditation Programme


Media enquiries

ABPI Press Office
Tel: +44 (0) 20 7747 1410 or +44 (0) 20 7747 1441
Mobile: +44 (0) 7850 312064 or +44 (0) 7808 641811 
Email: pressoffice@abpi.org.uk  


Notes to editors

The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.

Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. Our members supply 90 per cent of all medicines used by the NHS, and are researching and developing over two-thirds of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.

 The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry, for statutory consultation requirements including the pricing scheme for medicines in the UK.

Print this page icon Print this page
Please choose the subject of your enquiry from the list below:
Code to enter for submitting the form
Enter the above code here:
Can't read? Try different words.